AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories

Acquisition Company update Drug approval AI-generated analysis

πŸ“Š As of October 1, 2026, AbbVie trades at a 7.31x trailing sales multiple compared to Eli Lilly's 13.26x, reflecting slower growth but stronger cash generation.

πŸ’° AbbVie generated $16.87 billion in levered free cash flow in the trailing period, which is $5.8 billion more than Eli Lilly despite Lilly's higher revenue.

🏭 AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics on September 3 to add zumilokibart and APG273 to its pipeline.

πŸ“ˆ Analyst BofA raised its price target for AbbVie to $282 on September 8, maintaining a Buy rating after incorporating the new Apogee assets into estimates.

πŸ’Š Phase 2 data for zumilokibart (ABBV-295) showed weight reductions of 7.8% to 9.8% at Week 12, with every-other-week dosing achieving 9.7% reduction.

πŸ“‰ The Apogee acquisition is expected to dilute AbbVie's adjusted EPS by $0.14 in 2026 and about $0.46 in 2027 before becoming accretive in 2032.

🏦 Institutional ownership increased significantly, with Citadel increasing its position by 547% and AQR Capital Management by 127% in the second quarter of 2026.

πŸ’΅ AbbVie offers a forward dividend yield of 2.63%, contrasting with Eli Lilly's 0.58% yield, reflecting different capital allocation priorities.

πŸ“‰ AbbVie carries $70.89 billion in debt with a debt-to-EBITDA ratio of 2.28 times, which is higher than Eli Lilly's 1.31x leverage.

Bullish Signals
  • AbbVie generated $16.87 billion of levered free cash flow in the trailing period, significantly outpacing Eli Lilly's cash generation despite lower revenue growth.
  • The company reaffirmed its 2026 adjusted EPS guidance of $13.87 to $14.07 following the Apogee Therapeutics acquisition, demonstrating confidence in future earnings power.
  • Phase 2 data for zumilokibart met primary endpoints with weight reductions of 7.8% to 9.8% at Week 12, validating the pipeline's potential in the obesity market.
  • Major institutional investors are increasing exposure, with Citadel raising its position by 547% and AQR Capital Management by 127% in Q2 2026 filings.
  • Analyst BofA raised its price target to $282 from $276 on September 8, maintaining a Buy rating after adding zumilokibart to their investment thesis.
Risk Factors
  • The Apogee Therapeutics acquisition is expected to dilute adjusted EPS by $0.14 in 2026 and about $0.46 in 2027, delaying accretion until 2032.
  • AbbVie carries a higher debt load of $70.89 billion with a debt-to-EBITDA ratio of 2.28 times compared to Eli Lilly's more conservative 1.31x leverage.
Full Analysis
The article compares Eli Lilly (LLY) and AbbVie (ABBV), highlighting that while Lilly commands a premium valuation driven by rapid growth in its obesity pipeline, AbbVie offers a distinct profile characterized by stronger free cash flow generation and a higher dividend yield. As of October 1, 2026, Lilly trades at 13.26 times trailing sales with revenue up 49.6% year-over-year, whereas AbbVie trades at 7.31 times sales with revenue growth of 10.4%. AbbVie is leveraging its robust cash generation to fund significant pipeline expansion, including the recent $10.9 billion acquisition of Apogee Therapeutics which adds assets zumilokibart and APG273. The company reaffirmed its 2026 adjusted EPS guidance despite expected dilution from the deal, with analysts maintaining Buy ratings and raising price targets based on the potential of these new assets alongside its existing immunology franchise. Institutional positioning has increased for both companies in the second quarter of 2026, with major hedge funds like Citadel significantly increasing their stakes in AbbVie. The article concludes that the valuation gap between the two reflects their different financial strategies: Lilly's heavy reinvestment in manufacturing and growth versus AbbVie's focus on cash flow sustainability and shareholder returns.